AOBiome

12/03/2025

AOB Pharma receives European Medicines Agency (EMA) positive decision on the pediatric investigation plan (PIP), supporting future development of B244 for the treatment of mild to moderate atopic dermatitis in children, adolescents, and adults in the European Union (EU)

CAMBRIDGE, Mass., Dec. 2, 2025 /PRNewswire/ -- AOB Pharma, Inc. ("AOBiome"), a leading clinical-stage biotechnology company focusing on inflammatory skin conditions with their lead asset B244 for the treatment of mild to moderate atopic dermatitis (AD) and pruritus, received a positive decision on t...

10/08/2025

Veristat and AOBiome Therapeutics to Present at Clinical Outsourcing Group on Essential Elements of Effective Partnerships with CROs

SOUTHBOROUGH, Mass.--(BUSINESS WIRE)--Veristat, a global clinical research organization (CRO) and consultancy specializing in complex studies, announced today that it will participate in the Clinical Outsourcing Group – Bay Area 2025 conference, taking place October 21-22, 2025 at the Hyatt Regenc...

05/27/2025

AOB Pharma reveals new insights via metabolomic analysis of B244, supporting clinical readouts & suggesting investigation of potential new avenues for treatment

https://health.einnews.com/pr_news/814753976/aob-pharma-reveals-new-metabolomic-insights-of-b244-suggesting-investigation-of-potential-new-avenues-for-treatment

10/10/2024

AO+ Mist is Available Again!

The D23 AO+ Mist Topical Probiotic Spray is the same product that has been previously sold as AO+ MIST & Mother Dirt AO+ Restorative Mist.

https://aobiomecosmetics.com/products/d23

10/09/2024

USPTO Grants AOBiome Therapeutics Composition of Matter Patent for its Clinical Candidate B244

The newly issued patent covers Composition of Matter for AOBiome’s proprietary strain of Ammonia Oxidizing Bacteria (AOB), along with additional claims pertaining to a variety of related methods including use thereof in changing a composition of a skin microbiome of a subject, inhibiting microbial...

01/05/2024

https://www.aobiome.com/pressreleases/aob-pharma-and-maruho-enter-into-an-exclusive-license-agreement-for-aob-pharmas-topical-biologic-b244-for-the-treatment-of-inflammatory-indications-including-atopic-dermatitis-in-japan/

The license is exclusive for the territory of Japan and contains rights for future indications Maruho is responsible for conducting and bearing costs for development in Japan, which will be conducted jointly with AOB Pharma as part of a Global Phase 3 Study for Atopic Dermatitis encompassing Japan,....

05/25/2023

AOBiome Featured in Dermatology Times

B244 demonstrated significant levels of efficacy in patients with mild-to-severe atopic dermatitis and itch.

05/16/2023

AOBiome announces the publication of positive Phase 2b results in The Lancet’s eClinicalMedicine for B244 in the treatment of mild-to-moderate atopic dermatitis and moderate-to-severe pruritus.

https://www.aobiome.com/pressreleases/aobiome-announces-the-publication-of-positive-phase-2b-results-in-the-lancets-eclinicalmedicine-for-b244-in-the-treatment-of-mild-to-moderate-atopic-dermatitis-and-moderate-to-severe-pruritus/

AOBiome announces the publication of positive Phase 2b results in The Lancet’s eClinicalMedicine for B244 in the treatment of mild-to-moderate atopic dermatitis and moderate-to-severe pruritus. The peer-reviewed publication describes the significant effects of B244 in 4 weeks across key endpoints ...

04/06/2023

AOBiome Therapeutics Granted Composition of Matter Patent for its Clinical Candidate B244

The newly issued patent covers Composition of Matter for AOBiome’s proprietary strain of Ammonia Oxidizing Bacteria (AOB), along with additional claims pertaining to a variety of related methods including use thereof in changing a composition of a skin microbiome of a subject, inhibiting microbial growth on a subject’s skin, and treating or preventing a skin disorder.

AOBiome’s clinical candidate B244 has demonstrated clinical efficacy on multiple therapeutic indications including: Mild-to-Moderate Atopic Dermatitis and associated Moderate-to-Severe Pruritus, and mild-to-moderate Acne Vulgaris.

AOBiome is currently preparing for its Phase 3 trials for the treatment of Atopic Dermatitis (Eczema) and associated Pruritus (Itch).

AOBiome Therapeutics Granted Composition of Matter Patent for its Clinical Candidate B244 Apr 06, 2023 (PRNewswire via COMTEX) -- PR Newswire CAMBRIDGE,...

11/22/2022

AOBiome is focused on restoring a specific lost bacterium, Ammonia-Oxidizing Bacteria (AOBs), to human skin.

11/05/2022

This November AOBiome's CEO Todd Krueger be speaking at Microbiome Connect: USA, sharing his expertise and insights with the microbiome community.

Join him and 300+ leaders in the space for 3 exciting days of learning, networking, and forging successful partnerships at a pivotal time for microbial drug development.

Download the full agenda here: https://hubs.ly/Q01nTy-r0

See you there!

09/27/2022

Listed by under "50 Innovative companies to watch 2022", AOBiome Therapeutics is a leading clinical stage biotherapeutic company focusing on the research and development of drug for inflammatory condition.

https://thesiliconreview.com/magazine/profile/aobiome-therapeutics-transforming-human-health/

AOBiome Therapeutics – Transforming Human Health via Novel Microbiome-Based Therapies for Inflammatory Conditions